Take Homes in Genitourinary Cancers

In this video, Stephen Freedland, MD, discusses the results of the EMBARK study into high-risk, nonmetastatic biochemically recurrent prostate cancer, which he co-presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CHAARTED 2 cooperative group studies into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of transcriptomic signatures to aid in selection of patients with prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of new precision medicine therapies in prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of JNJ-6520 in prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of three studies into quality-of-life outcomes in metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CYCLONE 2 study into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a phase 1/phase 2 study into proteolysis-targeting chimeras in prostate cancer treatment, presented at ASCO Annual Meeting.

Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection of a bladder tumor and hypofractionated radiation therapy appeared safe for patients with muscle-invasive urothelial cancer.

A presentation at ASCO Annual Meeting supported the use of first-line axitinib and pembrolizumab in the treatment of patients with advanced renal cell carcinoma.